TY -的T1 -阿尔茨海默病的临床评估JF -神经学乔-神经病学SP - S7 LP - S10 - 10.1212 / W首页NL.49.3_Suppl_3。S7六世- 49 - 3,85盟——约翰·c·莫里斯Y1 - 1997/09/01 UR - //www.ez-admanager.com/conten首页t/49/3_Suppl_3/S7.abstract N2 -阿尔茨海默病的财团建立注册(CERAD)成立于1986年,开发标准化的方法来评估人与阿尔茨海默病(AD)和收集临床神经心理学,neuropathologic关于这种疾病的信息。CERAD临床电池。临床评估协议(表1)旨在为临床医生提供所需的最小信息做一个自信的诊断AD.1电池包括可靠和验证措施或那些历史悠久的价值。信息是通过半结构式访谈与病人和一个线人,一般病人的身体和神经系统检查,和短暂的认知尺度。问题是问关于疾病和伤害之前和抑郁症的症状。其他问题涉及的历史可能的痴呆症状,可能导致这些症状的药物,痴呆过程的持续时间。我们管理修改祝福评定量表Dementia2确定informant-reported改变工具和基本日常生活活动和简短的祝福Test3测量定位、内存和浓度。我们评估病人的语言、计算、和视觉空间的性能。实验室研究包括常规血图和生化屏幕,甲状腺功能测试和维生素b - 12的水平。 Neuroimaging of the brain by either CT or MRI is required. A protocol for obtaining and reading neuroimages has been developed.4 Global severity of dementia is staged in accordance with the Clinical Dementia Rating (CDR) scale.5(With evaluation of the cases until death, the stages assessed by the CDR have been validated and expanded to include profound [coded as 4] and terminal[coded as 5].)6 Diagnostic criteria for AD are those proposed by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association(NINCDS/ADRDA)7 modified to require memory loss of at least 12 months' duration (instead of 6 months), and … ER -